| Wallace, Daniel |
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 4 | 350 | Europe, Japan, US, RoW | Belimumab (GSK1550188), BEL (BENLYSTA) | GlaxoSmithKline | Systemic Lupus Erythematosus | 04/27 | 05/29 | | |
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 540 | Europe, US, RoW | Litifilimab, BIIB059, Placebo | Biogen | Lupus Erythematosus, Systemic | 09/26 | 03/27 | | |
|
NCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity |
|
|
| Recruiting | 3 | 621 | Europe, Canada, Japan, US, RoW | Dazodalibep, VIB 4920, MEDI 4920, Placebo | Amgen | Sjogren's Syndrome | 08/26 | 08/26 | | |
| Recruiting | 3 | 420 | Europe, Canada, US, RoW | ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Lupus Nephritis | 03/27 | 07/30 | | |
NCT02633163: Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) |
|
|
| Recruiting | 2 | 81 | US | Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion | Medical University of South Carolina | Systemic Lupus Erythematosus | 08/25 | 02/26 | | |
NCT00775476: Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine |
|
|
| Recruiting | 2 | 290 | US | N-acetylcysteine, Placebo | State University of New York - Upstate Medical University, Cedars-Sinai Medical Center, University of Rochester, Yale University, Penn State University, Hospital for Special Surgery, New York, Ohio State University, Oklahoma City VA Health Care System, St. Luke's Hospital and Health Network, Pennsylvania | Systemic Lupus Erythematosus | 03/27 | 09/28 | | |
ReLATE, NCT05845593: Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE |
|
|
| Recruiting | N/A | 200 | US | Decision Support Test | Ampel BioSolutions, LLC | Lupus Erythematosus, Systemic | 12/24 | 03/25 | | |
NCT05934149: Lupus Landmark Study: A Prospective Registry and Biorepository |
|
|
| Recruiting | N/A | 3500 | Canada, US | | Lupus Research Alliance | Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus | 12/33 | 12/33 | | |
| Avila, Erin |
NCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity |
|
|
| Recruiting | 3 | 621 | Europe, Canada, Japan, US, RoW | Dazodalibep, VIB 4920, MEDI 4920, Placebo | Amgen | Sjogren's Syndrome | 08/26 | 08/26 | | |
| Rubio, Jose Manuel |
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 3 | 225 | RoW | Belimumab | GlaxoSmithKline, ICON plc | Bronchial Diseases | 07/28 | 01/30 | | |
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 540 | Europe, US, RoW | Litifilimab, BIIB059, Placebo | Biogen | Lupus Erythematosus, Systemic | 09/26 | 03/27 | | |
|
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) |
|
|
| Recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab | GlaxoSmithKline | Eosinophilic Granulomatosis With Polyangiitis | 10/25 | 11/25 | | |
| Recruiting | 3 | 420 | Europe, Canada, US, RoW | ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Lupus Nephritis | 03/27 | 07/30 | | |
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
NCT05798117: An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 24 | Europe, US, RoW | YTB323 | Novartis Pharmaceuticals | Systemic Lupus Erythematosus, Lupus Nephritis | 10/26 | 10/26 | | |
EFINUTRILES, NCT05261529: Effects of an Intervention With EVOO and Physical Activity in Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | N/A | 90 | Europe | Extra Virgin Olive Oil (EVOO), Physical Exercise Program | Universidad de Granada, Consejería de Economía, Innovación y Ciencia. Proyectos de I+D+I en el marco operativo Feder Andalucía 2014-2020 | Lupus Erythematosus, Systemic | 12/22 | 06/23 | | |
NCT06101472: Rotational Stability and Clinical Response of the ASQELIO Toric Biaspheric Monofocal Lens. |
|
|
| Recruiting | N/A | 63 | Europe | ASQELIO Toric Biaspheric Monofocal Lens | AST Products, Inc. | Cataract | 08/24 | 10/24 | | |
| Recruiting | N/A | 120 | Europe | Pacemaker implantation with conduction system pacing using Lumenless leads, Pacemaker implantation with conduction system pacing using Stylet-driven leads | Puerta de Hierro University Hospital, Spanish Society of Cardiology | Left Bundle-Branch Pacing | 09/25 | 09/25 | | |
